Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On July 25, 2008, CHAD Therapeutics, Inc. (the "Company") disclosed that it received a letter from the American Stock Exchange ("AMEX" or the "Exchange") stating that the Company was not in compliance with Section 1003 of the AMEX Company Guide. On August 7, 2008, the Company responded to the Exchange's letter indicating that after careful consideration, the Board of Directors of the Company determined that, at the present time, the Company is not in a position to regain compliance with the continued listing standards within the time frame required by the Exchange. Accordingly, the Company notified AMEX that it intends to voluntarily withdraw its common shares from listing on the Exchange, with such withdrawal to become effective after the close of the market on August 29, 2008.
The Company expects to file a Form 25 with respect to the delisting with the Securities and Exchange Commission on or about August 18, 2008.
A copy of the press release issued by the Company on August 7, 2008 regarding the delisting from the Exchange is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The exhibit listed below is being furnished with this Form 8-K.

Exhibit Number Description 99.1 Press Release, dated August 7, 2008

---